WELLS FARGO & COMPANY/MN - BRIDGEBIO PHARMA INC ownership

BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 169 filers reported holding BRIDGEBIO PHARMA INC in Q4 2020. The put-call ratio across all filers is 0.33 and the average weighting 0.7%.

Quarter-by-quarter ownership
WELLS FARGO & COMPANY/MN ownership history of BRIDGEBIO PHARMA INC
ValueSharesWeighting
Q3 2023$2,186,679
-6.6%
82,923
-39.1%
0.00%0.0%
Q2 2023$2,342,038
+114.5%
136,165
+106.7%
0.00%
Q1 2023$1,092,042
+10353.2%
65,865
+4704.2%
0.00%
Q4 2022$10,447
-83.2%
1,371
-78.3%
0.00%
Q3 2022$62,000
-19.5%
6,332
-26.2%
0.00%
Q2 2022$77,000
-78.6%
8,581
-75.7%
0.00%
Q1 2022$359,000
-71.2%
35,318
-52.8%
0.00%
Q4 2021$1,247,000
-61.0%
74,749
+9.6%
0.00%
-100.0%
Q3 2021$3,196,000
+43.3%
68,196
+86.3%
0.00%
Q2 2021$2,231,000
-59.2%
36,611
-58.8%
0.00%
-100.0%
Q1 2021$5,469,000
+6.0%
88,790
+22.4%
0.00%0.0%
Q4 2020$5,159,000
+238.3%
72,535
+78.4%
0.00%
Q3 2020$1,525,000
-1.3%
40,656
-14.2%
0.00%
Q2 2020$1,545,000
+38.7%
47,374
+23.3%
0.00%
Q1 2020$1,114,000
+127.3%
38,421
+174.6%
0.00%
Q4 2019$490,000
+73.8%
13,990
+6.4%
0.00%
Q3 2019$282,00013,1460.00%
Other shareholders
BRIDGEBIO PHARMA INC shareholders Q4 2020
NameSharesValueWeighting ↓
Aisling Capital Management LP 6,068,125$160,016,45665.94%
Kohlberg Kravis Roberts & Co. L.P. 31,060,971$819,077,80528.79%
Cormorant Asset Management, LP 4,662,530$122,950,9167.17%
Frazier Life Sciences Management, L.P. 2,725,949$71,883,2754.77%
Octagon Capital Advisors LP 971,639$25,622,1203.94%
M28 Capital Management LP 121,200$3,196,0443.66%
VIKING GLOBAL INVESTORS LP 25,120,991$662,440,5332.69%
BOONE CAPITAL MANAGEMENT LLC 313,381$8,263,8572.61%
Fernwood Investment Management, LLC 235,620$6,213,2992.23%
SOUTHPORT MANAGEMENT, L.L.C. 15,000$395,5502.15%
View complete list of BRIDGEBIO PHARMA INC shareholders